In Brief: Amarin Perseveres With Vascepa Outcomes Trial, Cochrane Review Reignites Lucentis Cost Debate
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus Acura’s own appeal on abuse-deterrent opioid, TG Therapeutics gets FDA buy-in for ublituximab accelerated approval plan, and Amgen presents more analysis supporting heart failure drug ivabradine after Servier’s failed outcomes trial.